Sanofi says good results from flu vaccine with mRNA booster study
PARIS, Oct 7 (Reuters) – French healthcare company Sanofi (SASY.PA) said on Wednesday that it had found positive results from the first study into a high-dose influenza vaccine with a COVID-19 mRNA booster.
Sanofi said the interim results from the study of Sanofi’s Fluzone High-Dose Quadrivalent vaccine with Moderna’s (MRNA.O) COVID-19 mRNA investigational booster dose showed the vaccines had similar immunogenicity responses and a similar safety and tolerability profile.
“These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population,” said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.
